A gloved hand holds a control.

A laboratorian prepares a run of ARUP’s metagenomic sequencing assay.

October 27, 2026

New Sequencing Technology Positions ARUP for the Future of Infectious Disease Detection

ARUP has completed a CDC-funded metagenomic sequencing project that strengthens emerging pathogen

AAP 2026 Visit booth 2641. A tray with assorted test tubes.

Visit ARUP at booth #2641 to learn about the latest advancements in laboratory medicine to better support pediatric patients.

September 28, 2026

Supporting Pediatric Care: ARUP To Showcase Tests at AAP 2026

Discover how ARUP is advancing pediatric care through innovations in genomics, infectious disease, allergen testing, and more

Image of newborns crossed feet with a hospital ID tag around the left ankle.

This Newborn Screening Awareness Month, learn how updated ARUP Consult® topics support clinicians with evidence-based recommendations for diagnostic testing, monitoring, and genetic testing.

September 16, 2026

In Recognition of Newborn Screening Awareness Month: Updated ARUP Consult Resources…

During Newborn Screening Awareness Month, explore updated ARUP Consult® resources that

Text text text

Attendees will have the unique opportunity to tour ARUP Laboratories during the 2026 AMLI Annual Meeting.

August 4, 2026

ARUP Experts To Present on Emerging Immunology Topics at the 2026 AMLI Annual Meeting

ARUP pairs analytical rigor with specialty expertise in immunopathology to provide reliable

Screenshot of dashboard that shows the Cyclospora positivity rates

ARUP Laboratories observed Cyclospora positivity rates increase from very low levels to unprecedented levels within a short period of time, highlighting the importance of providing clinicians and laboratorians with timely disease surveillance data, said Ben Bradley, MD, PhD, ARUP head of clinical operations for Infectious Disease.

August 3, 2026

ARUP Laboratories Adds Cyclospora Data to Infectious Disease Dashboard Amid National Outbreak…

ARUP Laboratories’ Infectious Disease Test Positivity Trends Dashboard now includes

Image of small neoplastic populations

ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes small neoplastic populations with greater sensitivity than conventional flow cytometry while requiring less specimen volume.

July 20, 2026

ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple…

ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes neoplastic